GLP-1 Beyond Weight Loss: Every FDA-Approved Indication

Every Indication at a Glance

Cardiovascular Risk Reduction

This was the approval that changed how the medical community talks about these drugs. Wegovy became the first weight loss medication also approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease.

The significance is that it reframed semaglutide from a drug that treats a risk factor into a drug that reduces hard outcomes - heart attack, stroke, and cardiovascular death. That is a much higher evidentiary bar, and it is why cardiologists began prescribing these medications rather than only endocrinologists and obesity specialists.

Beyond the obesity population, semaglutide has been characterised in the literature as a key medication for cardiovascular management in type 2 diabetes, where it improves glycemic control, reduces major adverse cardiovascular events, and slows chronic kidney disease progression.

MASH and Liver Fibrosis

The FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH and moderate to advanced liver fibrosis - the first GLP-1 therapy approved for this progressive liver disease.

MASH stands for metabolic dysfunction-associated steatohepatitis, previously known as NASH. It is the more serious form of fatty liver disease, where fat accumulation is accompanied by inflammation and liver cell damage that can progress to fibrosis, cirrhosis, and liver failure. It is strongly linked to obesity, insulin resistance, and type 2 diabetes - and it has historically had almost no effective drug treatments.

What "Accelerated Approval" Means

Accelerated approval is granted based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than on final outcomes like liver failure or death - because waiting for those outcomes in a slow-progressing disease would take many years. Confirmatory trials continue after approval.

This is a real approval that supports prescribing and coverage, but it is worth understanding that the evidence standard differs from a standard approval.

For a ranked look at the options here, see our best GLP-1 for fatty liver guide.

Chronic Kidney Disease

The FDA approved Ozempic (semaglutide) to reduce the risk of worsening kidney disease, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease - reported as the only GLP-1 receptor agonist carrying this indication.

The approval applies to semaglutide 1.0 mg, and both FDA and EU regulators have expanded semaglutide labelling in this direction.

Diabetic kidney disease is a leading cause of kidney failure and dialysis. Until relatively recently, the options for slowing it were limited to blood pressure and glucose control plus a small number of drug classes. Adding a GLP-1 with demonstrated kidney outcome benefits is a meaningful expansion.

Obstructive Sleep Apnea

Zepbound (tirzepatide) is the first and only prescription medicine FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Before this, no drug of any kind had been approved for OSA - treatment was entirely mechanical.

The approval rests on the SURMOUNT-OSA programme, in which tirzepatide reduced sleep apnea severity by up to nearly two-thirds alongside reductions in hypoxic burden, systolic blood pressure, and inflammation markers.

Because OSA is dramatically underdiagnosed, this indication is one of the most commonly missed coverage routes. Many people with obesity have undiagnosed moderate-to-severe OSA and have never had a sleep study.

Full detail in our Zepbound for sleep apnea guide and our ranked options for OSA.

Why the Brand Name Matters, Not the Molecule

This is the detail that trips up the most people, and it has real financial consequences.

Insurers authorise by product and indication, not by molecule. Semaglutide is the same drug whether it is sold as Ozempic, Wegovy, or Rybelsus - but each brand carries different approved indications, and a plan will not automatically extend coverage from one to another.

The practical implication: make sure your prescriber writes for the brand whose indication matches your condition. Someone with type 2 diabetes and CKD needs Ozempic, not Wegovy. Someone with obesity and sleep apnea needs Zepbound, not Mounjaro. Getting this wrong is a common reason for denial.

For the tirzepatide version of this problem specifically, see our Mounjaro vs Zepbound comparison.

Using These Indications for Coverage

Many insurance plans exclude weight loss medications as a category. Almost none exclude treatment for cardiovascular disease, liver disease, or kidney disease. That asymmetry is the opportunity.

A Practical Checklist

1. Take stock of your actual diagnoses. Established cardiovascular disease, type 2 diabetes with CKD, diagnosed MASH with fibrosis, or moderate-to-severe OSA each open a different route.
2. Get the objective documentation. A sleep study with an AHI value, elastography or biopsy staging for MASH, eGFR and albuminuria for CKD, and cardiac history for the CV indication. Insurers want numbers, not symptoms.
3. Get tested for what you might have but have not confirmed. OSA is dramatically underdiagnosed, and MASH is frequently silent. Both are worth investigating on their own merits regardless of medication.
4. Match the brand to the indication when your prescriber writes the prescription.
5. Submit under the condition-specific indication, not the obesity indication, if you qualify.
6. Appeal a first denial, and request a peer-to-peer review if the written appeal fails.

Frequently Asked Questions